Loading peptide profile…
Loading peptide profile…
Longevity Category
THE PAIN ELIMINATOR
Dermorphin is an opioid peptide originally isolated from frog skin. Older human studies examined pain reflexes and postoperative pain relief. It is not FDA approved.
Severe chronic pain patients · Those unresponsive to other pain medications · Research applications only · NOT for casual use
0.1-1 mg daily (research only)
Short-term use only
Clinical team guidance, not medical advice.
Based on what vendors sell, not a recommendation.
Injection
Sold as vials by 4 vendors
By mouth
Not sold by vendors we track
Nasal spray
Not sold by vendors we track
Not FDA approved, research use onlyHow we review these guides15 research sources
In volunteers, dermorphin raised the threshold of a pain-related spinal reflex. Naloxone only partly reversed the observed response.
A randomized study compared dermorphin with morphine and pentazocine. The older report described longer pain relief with dermorphin.
No. This profile records Dermorphin as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.
Dose: 0.1-1 mg daily (research only). Schedule: daily. Cycle: Short-term use only. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 15 curated or current research sources. Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the Dermorphin research sourcesReported side effects of Dermorphin include Urinary retention, Vomiting, and Headache. They are reported or occasional reactions, not a prediction of what any one person will experience.
Dermorphin has an editorial safety grade of D (High Risk). Older human studies exist. A 150-patient comparative trial reported urinary retention, vomiting and headache, without significant differences between groups; it does not establish a modern safety profile. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
In rats, dermorphin and fentanyl both elicited a similar immediate apnea (breathing stop). The recovery of respiratory response was much faster after dermorphin (0.5 min) than after fentanyl (30 min) in rats. In rats, dermorphin pretreatment blocked fentanyl-induced apnea, while fentanyl pretreatment failed to affect the dermorphin-induced apnea.
In-stock prices from 4 vendors, checked Nov 7, 2026.
Market evidence
We found certificates from a few of the Dermorphin vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
Synthetic gastric peptide studied almost entirely in animals
from $1.10/mg · 243 vendorsNº 001 / 006Nine-amino-acid peptide with sparse, dated human studies
from $1.95/mg · 146 vendorsNº 002 / 006Synthetic pineal tetrapeptide from one research lineage
from $0.45/mg · 158 vendorsNº 003 / 006A copper binding tripeptide studied in skin and animal models
from $0.12/mg · 239 vendorsNº 004 / 006An EDR tripeptide studied in nerve cell models
from $1.25/mg · 86 vendorsNº 005 / 006Brain-acting melanocortin peptide, FDA-approved as Vyleesi for HSDD
from $1.65/mg · 128 vendorsNº 006 / 006